Can lumbar puncture help to identify patients with incipient Alzheimer's disease?

Nature Clinical Practice Neurology

Volumn 2, Issue 10, 2006, Pages 530-531

  Bouwman, Femke H ^a   van der Flier, Wiesje M ^a   Scheltens, Philip ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; THREONINE;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DIAGNOSTIC VALUE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; LEWY BODY; LUMBAR PUNCTURE; MEMORY DISORDER; MULTIINFARCT DEMENTIA; OUTCOMES RESEARCH; POSTDURAL PUNCTURE HEADACHE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

EID: 33749001426     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0295     Document Type: Short Survey

References (6)

1. Petersen RC et al. (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56: 303-308
2. Blennow K and Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613
3. Zetterberg H et al. (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352: 67-69
4. Bouwman FH et al. (2006) CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging [doi:10.1016/j.neurobiolaging.2006.05.006]
5. Lewczuk P et al. (2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 52: 332-334
6. Schoonenboom NS et al. (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: Implications for use in clinical practice. Clin Chem 51: 189-195